ENVB - Company ID 0000890821
The table below shows Enveric Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $345.97K | $402.42K | $1.26M | $746.37K | $802.72K | $565.00K |
| SG&A |
Enveric Biosciences, Inc. reported annual revenue of $39.91M for fiscal year 2019. That is down 7.2% from $43.00M in fiscal 2018. Over the 7 fiscal years shown, annual revenue grew from $6.14M (FY 2014) to $39.91M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.25M |
| $1.43M |
| $1.22M |
| $1.36M |
| $1.20M |
| $1.25M |
| Operating income | -$1.63M | -$1.87M | -$2.52M | -$2.19M | -$2.08M | -$1.90M |
| Income tax | - | - | - | - | - | - |
| Net income | -$1.63M | -$1.87M | -$2.52M | -$2.18M | -$2.08M | -$1.88M |
| EPS (diluted) | -$1.08 | -$10.81 | -$0.97 | -$14.58 | -$43.10 | -$3.72 |